Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Instil Bio Inc. and Immuneonco Biopharmaceuticals Inc. laid out their global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510 (IMM-2510) in front-line non-small-cell lung cancer ...

Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Learn about common mistakes in manual ELISA assays and discover how automation can eliminate errors, improving accuracy, ...

A team of researchers has discovered an antibody that can counter all known variants of the COVID-19 virus. The scientists also claim the antibody can also resist distantly related viruses that ...

Antibodies are proteins that play a crucial role in the immune response by recognizing and binding to specific antigens ... The incorporation of non-natural amino acids, such as pH-sensitive ...

TPO molecules may also differ with respect to their three-dimensional structure, extent of glycosylation and heme binding ... range" values may represent non-specific assay "noise" and may ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

The other heavy chain of the vaguely Y-shaped antibody targets CD38, another myeloma target. Binding to all three targets brings the T cell and the tumor together, Konto said. From there ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is in the process of developing its anti-Tau antibody VY7523 for the treatment of patients with Alzheimer's Disease [AD] in a phase 1a single-ascending ...